BeOne Medicines (ONC) Research & Development (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Research & Development data on file, last reported at $541.2 million in Q1 2026.

• Quarterly Research & Development rose 12.31% year-over-year to $541.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (up 11.68% YoY) and the FY2025 annual result came in at $2.1 billion, up 9.86% from the prior year.
• Research & Development eased to $541.2 million in Q1 2026 per ONC's latest filing, from $615.4 million in the prior quarter.
• Across five years, Research & Development topped out at $615.4 million in Q4 2025 and bottomed at $378.2 million in Q2 2022.
• The 5-year median for Research & Development is $460.6 million (2024), against an average of $474.1 million.
• The widest annual swing landed in 2022, when Research & Development surged 180.18%; it then grew 4.61% in 2025.
• Tracing ONC's Research & Development over 5 years: stood at $446.0 million in 2022, then increased by 10.75% to $494.0 million in 2023, then advanced by 9.72% to $542.0 million in 2024, then gained by 13.54% to $615.4 million in 2025, then decreased by 12.06% to $541.2 million in 2026.
• Per Business Quant, the three latest ONC Research & Development figures stand at $541.2 million (Q1 2026), $615.4 million (Q4 2025), and $523.7 million (Q3 2025).

Peer Comparison